The Filing Desk

Rocket Pharmaceuticals

RCKT · Nasdaq · Health Care · Financials, fiscal 2016 to 2025

RCKT · Last close · November 19, 2026
$2.11
Value Rocket Pharmaceuticals yourself

Rocket Pharmaceuticals reported revenue of $0 million in fiscal 2025. Free cash flow was −$190 million. The diluted share count rose 17.2%.

Rocket Pharmaceuticals, Inc. Latest fiscal year ended December 31, 2025 10-K filed February 26, 2026 · 0001193125-26-076551 Updated
Revenue
$0M
 
Net margin
—
 
Net income
−$223M
 
Free cash flow
−$190M
 
Return on capital
−165.1%
32.5 pts
Market cap
$240M
Nov 19 close
P/E
—
Loss: no P/E

Net margin is net income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

What Rocket Pharmaceuticals does

Rocket Pharmaceuticals is a late-stage biotechnology company that develops gene therapies for rare, often fatal inherited diseases. A gene therapy delivers a working copy of a gene into a patient's cells. Rocket has no approved products and no product sales. Its work now centers on heart diseases caused by a single gene, using harmless modified viruses called AAV vectors to deliver the gene.

Its lead cardiovascular candidate, RP-A501, is for Danon disease, a rare inherited disorder that causes heart failure. Its other programs target forms of inherited heart disease. It also has KRESLADI, an investigational gene therapy for a rare immune disorder called LAD-I, which uses a patient's own modified blood stem cells. The FDA issued a complete response letter for it, and the company has submitted responses. It says it plans a scaled commercial effort for that very small patient group.

In July 2025, Rocket restructured and cut back its pipeline, de-prioritizing its Fanconi anemia and pyruvate kinase deficiency programs. It reduced its workforce by about 30%. It runs its own manufacturing plant in Cranbury, New Jersey. At December 31, 2025, it had 202 full-time employees.

Its biggest risks, as it describes them

  • It has lost money in every period and will need more funding, which may not be available on acceptable terms.
  • Its gene therapies use new technology, and trials may be delayed or fail to show safety and effectiveness.
  • It may never win approval for its candidates in the U.S. or EU, including KRESLADI after its FDA letter.
  • Its restructuring may not save as much as it expects, and it faces securities lawsuits.
  • Production problems or rule violations at its own manufacturing facilities could delay or limit supply.
From Rocket Pharmaceuticals's annual report on Form 10-K, filed February 26, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

Rocket Pharmaceuticals lost money in fiscal 2025: a net loss of $223 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments389356408372189
Debt incl. finance leases2121212121
Net debt (negative means net cash)−368−335−386−351−168
Net debt to EBITDA—————
Debt to equity0.1x0.0x0.0x0.1x0.1x
Interest coverage−56.2x−120.5x−138.5x−144.9x−122.5x
Current ratio17.7x9.3x7.8x9.3x6.4x
Quick ratio17.7x9.3x7.8x9.3x6.4x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Rocket Pharmaceuticals' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

What Rocket Pharmaceuticals says to expect

  • Cash: funding of planned operationsBased on its current operating plan, Rocket expects its cash, cash equivalents and investments as of September 30, 2026, to fund operations into the third quarter of 2028.
  • Pivotal trial: dosing and results timingRocket expects to complete pivotal trial dosing by mid-2027, with topline results anticipated in mid-2028.
The company's own words, from its earnings release (Form 8-K, Exhibit 99), filed November 12, 2026. They are its expectations, not ours, and not a forecast or price target from The Filing Desk. Replaced when the next release is out.

Insider trades

Over the 12 months between November 20, 2025 and November 19, 2026, 1 insider bought $34,400 of Rocket Pharmaceuticals shares on the open market, and 5 insiders sold $845,572.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
Nov 13, 2026Martin WilsonGeneral CounselSold4,087$2.25$9,196Form 4
Nov 13, 2026Gaurav ShahCEOSold3,020$2.25$6,795Form 4
Sep 11, 2026Martin WilsonGeneral CounselSold75,364$3.40$256,238Form 4
Aug 18, 2026Gaurav ShahCEOSold2,293$3.38$7,750Form 4
Aug 18, 2026Martin WilsonGeneral CounselSold631$3.38$2,133Form 4
Aug 13, 2026Martin WilsonGeneral CounselSold3,493$3.38$11,806Form 4
Aug 13, 2026Gaurav ShahCEOSold2,837$3.38$9,589Form 4
Aug 11, 2026Christopher James StevensChief Operating OfficerSold36,658$3.50$128,303Form 4
Aug 11, 2026Sarbani ChaudhuriSee RemarksSold4,701$3.50$16,454Form 4
May 21, 2026Gaurav ShahCEOSold55,684$3.09$172,064Form 4
May 19, 2026Gaurav ShahCEOSold2,409$3.01$7,251Form 4
May 19, 2026Martin WilsonGeneral CounselSold662$3.01$1,993Form 4
The latest 12 of 24 trades. Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score2 of 82 of 82 of 8
Rule of 40———
Altman Z''2.230.74−10.24
Accruals ratio−9.1%−9.0%−7.7%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailFail
Cash from operations is positiveFailFailFail
Return on assets rosePassFailPass
Cash from operations exceeds net incomePassPassPass
Debt fell relative to assetsFailFailFail
Current ratio roseFailPassFail
Share count didn't riseFailFailFail
Gross margin rose———
Revenue rose relative to assetsFailFailFail
F-score2 of 82 of 82 of 8
Companies that report no gross profit are scored on the other eight.

Compare

Put Rocket Pharmaceuticals side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
Rocket PharmaceuticalsFY25———−165.1%—2
Aardvark TherapeuticsFY25——————Compare
ABVC BioPharmaFY25−41.9%−2,416.0%————Compare
Acadia PharmaceuticalsFY2511.9%9.8%9.8%———Compare
Aclaris TherapeuticsFY25−58.2%−975.9%−603.4%———Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

10 years of figures

Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue0000000000
Revenue growth——————————
Gross profit——————————
Research and development6155358105126166186171142
Operating income−8−20−71−76−134−167−224−260−273−232
Net income−8−20−74−77−140−169−222−246−259−223
Diluted EPS (US$)−1.11−2.88−1.89−1.58−2.52−2.67−3.26−2.92−2.73−2.01
Diluted shares (millions)7739495563688495111
Cash flow
Cash from operations−6−16−54−65−75−121−178−195−210−190
Capital expenditure0122321881660
Free cash flow−6−17−55−88−95−129−186−211−216−190
Dividends paid0000000000
Share buybacks0000000000
Acquisitions0000000000
Stock-based compensation011413192931394437
Balance sheet at fiscal year end
Cash and short-term investments126100213304483389356408372189
Debt incl. finance leases—04145562121212121
Total assets13020251372591497552566528330
Total liabilities5655765874262746453
Shareholders' equity816194307504455490493463277
Margins and ratios
Gross margin——————————
Operating margin——————————
Net margin——————————
Free cash flow margin——————————
Rule of 40 (growth + FCF margin)——————————
Return on capital———−170.4%−170.1%−161.8%−147.0%−157.5%−197.7%−165.1%
Return on equity−63.3%−163.9%−71.1%−30.8%−34.5%−35.3%−47.0%−50.0%−54.1%−60.3%
Return on assets−6.2%−26.1%−54.9%−24.8%−29.0%−31.1%−42.3%−43.9%−47.3%−52.0%
Net debt to EBITDA——————————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Rocket Pharmaceuticals' Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Rocket Pharmaceuticals.